Prescient Therapeutics

Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies. Prescient’s technologies emanate from prestigious world class centres including Yale, Penn, Oxford and Moffitt. Targeted therapy: Prescient’s first in class targeted therapy – PTX-100 – is currently in clinical development and showing encouraging activity in diseases of unmet need. Cell therapies: Prescient owns the exclusive rights to two next-generation cell therapy platform technologies, OmniCAR and CellPryme – both with the potential to enhance CAR-T therapies and overcome challenges faced by current generation approaches